Business Wire

RSA Recognized in 2024 Gartner® Magic Quadrant™ for Access Management

5.12.2024 13:00:00 CET | Business Wire | Press release

Share

RSA, the security-first identity leader, announced today that RSA® ID Plus, the world’s most secure identity and access management (IAM) platform has been named a Niche Player in the 2024 Gartner® Magic Quadrant™ for Access Management.

With only ten organizations named to the Gartner report, RSA believes that the Magic Quadrant signals the world’s top IAM vendors. ID Plus brings comprehensive identity protection to some of the world’s most security-sensitive organizations across banking, securities, insurance, and government. Available as SaaS, on-premises, or in hybrid configurations, ID Plus offers organizations flexibility in deployment and specialization in high-security workforce environments. Through various subscription models featuring a range of editions and add-ons, ID Plus meets diverse needs, supporting the evolving workforce requirements and regulatory landscapes throughout North America, South America, Europe, and the Asia-Pacific markets.

RSA believes that several capabilities and strengths contributed to ID Plus being listed in the 2024 Gartner Magic Quadrant for Access Management, including:

  • High customer satisfaction and retention
  • Specialization in workforce use cases, particularly for high-security verticals
  • Broad support for cloud, hybrid, and on-premises environments
  • A high-availability, high-security failover process that ensures uninterrupted access even during cloud outages
  • Integrations with existing data and applications that enable buyers to maintain local configurations

“For decades, RSA has set the standard in secure authentication, but our story goes far beyond that. Seeing ID Plus break into the 2024 Gartner Magic Quadrant for Access Management and being recognized as a workforce security specialist, we feel, highlights the work we’ve done to develop a unified identity platform capable of securing the entire identity lifecycle and protecting highly regulated industries,” said RSA CEO Rohit Ghai.

“We feel that being named to the Gartner Magic Quadrant establishes RSA as one of the world’s top ten IAM vendors, and we’re not planning on going anywhere,” said RSA Chief Product and Technology Officer Jim Taylor, who detailed why workforce access management challenges organizations, how RSA supports customer access management, and the organization's access management roadmap in a new blog post. “Workforce access management is hard because it demands balancing security, usability, and scalability without getting any component wrong. I’d rather RSA be known as a workforce security specialist than an access generalist: that’s always been where RSA delivers the most value and what our customers need. With hundreds of IAM vendors worldwide, this recognition validates our commitment to delivering the full range of access, authentication, governance, and lifecycle capabilities that every organization requires.”

“While we may be new to the Magic Quadrant, security-first industries have relied on our access management solutions for years,” said RSA President and Chief Business Officer Greg Nelson. “Security-first leaders in government, finance, energy, and other regulated industries have long trusted RSA to deliver robust identity security solutions. We believe this recognition from Gartner underscores the strength of our strategy and reinforces our commitment to lead across every component of identity.”

Recent enhancements to ID Plus—including expanded identity insights, Bring Your Own Identity (BYOI) options, and OAuth 2.0 capabilities supporting machine-to-machine and IoT access—will bring further workforce security depth to the solution. RSA will introduce mobile passkey functionality, advanced directory enhancements, and increased AI and machine learning capabilities to assist security administrators in mitigating evolving threats.

RSA will showcase these innovations at the Gartner Identity & Access Management Summit from December 9-11 in Grapevine, Texas. Attendees are invited to visit RSA at booth 633 to experience demonstrations of the latest passwordless authentication and identity governance and administration (IGA) advancements. Book your demo with RSA at the Gartner IAM Summit now.

Resources

Read Jim Taylor’s blog post
Book your demo with RSA at the Gartner Identity & Access Management Summit
Start your free, 45-day trial of RSA ID Plus today

About RSA

The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205057055/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye